Key Takeaways BAYRY says asundexian met primary efficacy and safety endpoints in the OCEANIC-STROKE study.The drug cut ischemic stroke risk versus placebo when added to antiplatelet therapy.BAYRY plans global filings after results showed no rise in ISTH major bleeding with asundexian.Bayer AG (BAYRY) announced that pipeline candidate asundexian met primary efficacy and safety endpoints in late-stage OCEANIC-STROKE Study in secondary stroke prevention.Results from the study showed that asundexian 50 mg once ...